Rescue Endovascular Treatment for Emergent Large Vessel Occlusion With Underlying Intracranial Atherosclerosis: Current State and Future Directions

Sami Al Kasab 1,2*, Eyad Almallouhi 1,2 and Alejandro M. Spiotta 1

1 Department of Neurology, Medical University of South Carolina, Charleston, SC, United States, 2 Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States

Intracranial atherosclerosis (ICAS) is one of the most common causes of stroke worldwide and is associated with high risk of stroke recurrence. While the most common clinical presentation is acute–subacute transient ischemic attack or ischemic stroke, occasionally, patients with underlying ICAS present with acute occlusion of the affected vessel. Diagnosis and endovascular management of ICAS-related emergent large vessel occlusion (ELVO) can be challenging. Herein, we review the current evidence supporting endovascular management of ICAS-related ELVO and discuss future directions.

Keywords: stroke, thrombectomy, intracranial atherosclerosis, stenting, rescue

INTRODUCTION

Endovascular treatment is the standard of care for acute ischemic stroke patients with emergent large vessel occlusion (ELVO) (1). The benefit from mechanical thrombectomy (MT) is largely driven by achieving successful revascularization (2). However, a subgroup of patients undergoing MT may have refractory occlusions due to underlying intracranial atherosclerosis (ICAS) with resultant residual severe stenosis or unstable plaque and in situ thrombosis/re-occlusion (3). Management of this group of patients can be challenging and commonly requires rescue therapy with intra-arterial antiplatelet, thrombolitics, anticoagulation, angioplasty, stenting, or combination of treatment modalities. The safety and efficacy of such rescue treatments have not yet been established, and current evidence is largely driven from small retrospective case series (4–6).

In addition, the current literature on the prevalence and endovascular treatment of ICAS-related ELVO mostly comprised Asian studies. It is known that ICAS is more prevalent in Asian population; studies evaluating outcomes of angioplasty and/or stenting in Asian population showed promising results; on the other hand, strong evidence from randomized controlled trials in North America and Europe showed clear advantage of medical management over angioplasty/stenting (7–9). In this review, we discuss the prevalence, pathophysiology, and the available evidence supporting management of ICAS-related ELVO and provide insights on future directions.

PREVALENCE, PATHOPHYSIOLOGY, AND DIAGNOSIS

The prevalence of ICAS-related ELVO ranges from 1.9 to 30% depending on few factors including definition used, the study population included, and the involved vascular territory in the published literature (10–12). ICAS is much less common in Western population compared with Asian
population (12, 13). In Asian population, ICAS-related ELVO is estimated to be responsible for approximately one-third of ELVOS (9, 13); conversely, ICAS-related ELVO is much less common in Western population and is responsible for <10% of all ELVOS (14). This likely reflects the fact that ICAS is more common in Asian than Western population (15). Previous studies evaluating risk factors for ICAS-related ELVO showed that compared with embolic ELVO, ICAS-related ELVO patients are younger and more likely to be men. In addition, patients with ICAS-related ELVO have higher incidence of hypertension, hyperlipidemia, and diabetes mellitus and lower incidence of atrial fibrillation (4). While the abovementioned risk factors are suggestive of ICAS, diagnosis of ICAS-related ELVO poses a major challenge.

The mechanism of acute/subacute strokes with ICAS had been extensively studied before (16–19). The main mechanisms responsible for TIA/stroke with ICAS are as follows: (a) in situ thrombosis, (b) branch atheromatous disease, (c) hemodynamic compromise, (d) artery-to-artery embolism, or (e) combination of the mechanisms (20, 21). However, for ICAS-related ELVO, the main proposed mechanism is ruptured, unstable plaque with subsequent in situ thrombosis and resultant occlusion and re-occlusion (22, 23).

Evaluating pre-thrombectomy imaging can be helpful in identifying patients with ICAS. Findings such as calcification of the internal carotid artery on computed tomography, clot burden on computed tomography angiography (CTA), and magnetic resonance imaging could be suggestive of ICAS as the underlying mechanism of ELVO given that ICAS patients have lower clot burden (24, 25). The finding of calcifications on baseline CT imaging particularly in the posterior circulation is indicative of ICAS (26). Previous studies have also suggested the use of baseline infarct core volume to predict ICAS. Due to better collateral circulation in patients with ICAS-related ELVO compared with embolic ELVO (13), patients with ICAS are expected to have lower infarct volume. Baseline infarct volume was assessed in one study of patients with embolic ELVO and ICAS ELVO. Patients with ICAS ELVO had significantly lower baseline infarct volume (14 vs. 54 ml in ICAS vs. embolic ELVO, respectively, p ≤ 0.001) (24).

The importance of collateral status in (a) aiding with the diagnosis of ICAS and (b) determining infarct volume has been studied before. A study by Lee et al. assessed leptomeningeal collateral status using the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) collateral grading scale (27) in patients with middle cerebral artery (MCA) M1 segment occlusion. In this study, 8/10 (80%) patients with ICAS-related ELVO had excellent collateral grade compared with 19/43 (44.2%) of patients with embolic ELVO (p = 0.032) (13). A recent study by Baek et al. investigated the utility of pre-procedural leptomeningeal collateral status in predicting ICAS-related ELVO (28). The authors used CTA to assess collateral status utilizing Tan’s collateral grading system (29). In brief, Tan’s system has four grades, from A indicating absent collateral supply to D indicating complete collateral supply of 100% of the MCA territory (29). In the study by Baek et al. 40 patients with ICAS-related ELVO and 186 with embolic ELVO were included. Complete (100%) collateral status was significantly higher among patients with ICAS-related ELVO (52.5% vs. 20.4%) (28).

Intra-procedurally, diagnosis of ICAS as the underlying mechanism of ELVO is challenging and often times is made only following initial revascularization attempt. Occasionally, the use of stent retriever (SR) could help establish the diagnosis given that SRs often show full proximal and distal deployments but partial deployment across the stenotic area (truncal deployment) (Figure 1). In addition, the presence of robust leptomeningeal collateral on initial angiography is more likely to be found with ICAS compared with embolic ELVO (13). Nevertheless, there are currently no universally accepted diagnostic criteria; however, one study evaluated the inter-rater reliability of using the presence of any of the following: (a) residual fixed stenosis following MT that measures >50% or (b) mild–moderate stenosis with re-occlusion on follow-up angiography or (c) evidence of distal hypoperfusion and ruling out of other pathologies such as dissection (Figure 2). These criteria were validated in a previous study showing acceptable inter-rater reliability (9). While the presence of residual fixed severe stenosis following MT is the most straightforward diagnosis of ICAS, the presence of re-occlusion without associated significant stenosis can arguably be secondary to an organized partially removed thrombus. The presence of re-occlusion, however, is much less common in embolic ELVO compared with ICAS-related ELVO. A number of studies evaluated the rate of intra-procedural re-occlusion in ICAS-related ELVO compared with embolic ELVO. The rate of intraprocedural re-occlusion had been shown to
be significantly higher in ICAS-related ELVO; most studies have reported a rate of 30% for ICAS-related ELVO compared with <3% for embolic ELVO (4, 30). A study by Kang et al. evaluated the rate of instant re-occlusion during MT; in their study, 40/132 (30%) had in situ thrombosis with re-occlusion; and all of those patients had underlying ICAS on follow-up imaging (31). The underlying mechanism of re-occlusion is not well studied. It is postulated that an underlying unstable plaque resulting in platelet activation followed by in situ thrombosis could result in re-occlusion. A postmortem study suggested underlying fibrous cap disruption and sub-intimal dissections as possible explanation of in situ thrombosis and resultant re-occlusion (30–32). Some interventionists repeat angiography 5–10 min after successful revascularization but with residual mild–moderate stenosis. Repeat angiography helps in evaluating for re-occlusion and ruling out other etiologies such as vasospasm.

**DISCUSSION**

ICAS-related ELVO poses a major therapeutic challenge; the main challenge is the tendency of re-occlusion of the affected vessel, or residual stable fixed severe stenosis impairing distal flow. The optimal treatment strategy for such cases is unclear; however, it often involves the use of angioplasty and/or stenting to achieve successful revascularization. When assessing the safety and efficacy of angioplasty and stenting for ICAS, it is important to distinguish this group of patients from patients with ICAS presenting with transient ischemic attack or subacute stroke. In the latter, there is strong evidence that medical management is superior to endovascular treatment with angioplasty and/or stenting; this is derived from the peri-procedural complications related to angioplasty and advancement in medical management (33, 34). In the ICAS-related ELVO group, however, patients are at risk of suffering from a large, often disabling stroke if left with unsuccessful revascularization. Treatment options depend on the clinical scenario, mainly related to the angiographic appearance following recanalization and whether there is re-occlusion of the vessel vs. residual severe flow-limiting stenosis. Treatment options could include intra-arterial treatment with thrombolytics, antiplatelets, angioplasty, and/or stenting. The evidence of the abovementioned treatment options and approaches is not strong and derived largely from small retrospective case series. Importantly, the vast majority of these studies were carried out in Asia with only few studies coming from the United States and Europe. Aside from ICAS being more common in Asian patient population, similar to ICAS in the non-emergent setting, studies coming from the United States and Europe have shown different results as compared with those coming from Asia (5, 6, 35). While it remains unclear why there are such stark differences in treatment effects between Asian and Western patient populations with ICAS, studies have suggested genetic, socioeconomic, and dietary differences as contributing factors (14, 20). A study by Yoon et al. evaluated the safety of emergent angioplasty with or without stenting in patients with ICAS-related ELVO; the authors reported more favorable outcomes in the ICAS group compared with the control group, with no difference in symptomatic intracranial hemorrhage or mortality (36). Conversely, a study from Spain by Matias-Guiu reported longer procedural times; higher mortality and lower rates of good functional outcomes in ICAS-related ELVO require rescue therapy with angioplasty with or without stenting (37). This study, however, only had 15 patients with ICAS (10, 11). Other studies reporting on comparably small sample sizes carried out in the United States and Europe have reported conflicting results with regard to rates of successful revascularization, complication rates, and long-term outcomes (4). The small sample size in those studies is likely due to the fact that ICAS is less prevalent in Western compared with Asian population (38).

In addition, the thrombectomy approach and whether an SR vs. a direct aspiration first pass technique (ADAPT) is used initially may influence the final rescue therapy treatment decision. There are advantages to each treatment approach. Although current evidence supports similar efficacy and safety
profile for SR and ADAPT as frontline MT techniques, the vast majority of patients included in these trials were embolic ELVOs (39, 40). Therefore, it remains unclear what the best frontline MT treatment for ICAS-related ELVO. Advantages of SR frontline thrombectomy approach include the following: (A) Early diagnosis. Given that SR takes the shape of the stenotic area (truncal occlusion), SR could help identify the lesion following the deployment of SR (Figure 1) and therefore earlier treatment planning. (B) With SR deployment, there is partial flow restoration, which could in theory reduce clot burden. (C) Some interventionists advocate for SR as frontline approach for ICAS-related lesions due to its ability to completely engulf the clot, whereas with aspiration, the aspiration catheter tip could be against the plaque; however, with newer larger caliber aspiration catheters where there is full engagement of the lesions, this argument is unlikely to be valid (Figure 1B). The main advantages of using ADAPT as frontline treatment for ICAS-related ELVO include (a) less interaction with the plaque as opposed to SR, which could lead to further endothelial damage, plaque inflammation, and clot propagation (41, 42). Furthermore, in perforator-rich segments such as M1 segment of the MCA, and midsegment of the basilar artery, the use of SR could lead to perforator occlusion “snow plowing,” which is less likely to happen with ADAPT (43). Nevertheless, to our knowledge, there is no study to date that compared SR vs. ADAPT as frontline approach for patients with ICAS-related ELVO.

The approach to rescue therapy used depends on underlying lesion visualized following first successful thrombectomy pass, baseline core infarct, and involved segment. Once ICAS is identified, our practice is to repeat after waiting for 5–10 min and re-evaluate with follow-up angiography. In cases of residual severe stenosis without evidence of re-occlusion, angioplasty is performed first if lesion is not involving perforator-rich segment; if residual flow-limiting stenosis persists, stenting is then performed. In perforator-rich segments, we typically stent without balloon angioplasty (Figure 3). We avoid angioplasty in perforator-rich segments such as M1 and midbasilar segments, given associated risk of perforator occlusion. Angioplasty is typically performed using non-compliant balloon sized to the diameter of the normal intracranial segment proximal to the affected segment. Our practice has been to perform submaximal angioplasty to avoid perforator occlusion and reduce the amount of plaque disruption. A meta-analysis by Seyedaadat et al. evaluated 19 studies with 777 patients who underwent submaximal angioplasty for ICAS. The authors found 93% success rate with 3% stroke rate at 1 month (44), significantly lower rates than what were reported in SAMMPRIS (33) and VISSIT (5). In cases of re-occlusion, our practice has been to repeat MT and give a weight-based intra-arterial dose of tirofiban followed by stenting. Pre-stenting balloon angioplasty is performed in cases of associated severe flow-limiting stenosis (Figure 4).

The type of stent used in ICAS-related ELVO is also controversial. The ideal stent is one that is easy to deliver and has excellent radial force and low metal–vessel ratio. The Neuro-Form atlas stent is a self-expanding nitinol stent with hybrid cell structure. The stent has 6–12% vessel coverage and has a moderate radial force that is higher than flow diverters but lower than Wingspan stent (Stryker Neurovascular, Fremont, CA, USA). In our practice, we use Neuro-Form Atlas for ICAS-related ELVO with good success rate (45). In addition, balloon-mounted stents have recently emerged as potential effective stents in this population. The advantage of balloon-mounted stents is the added radial force as compared in Neuro-Form atlas (Stryker Neurovascular) and the pre-balloon angioplasty associated with deployment; however, due to their stiffness, navigating such stents could be challenging, particularly in tortuous anatomy. Mohammaden et al. recently evaluated the use of balloon-mounted stent in the treatment of symptomatic ICAS (46). Among 232 patients with symptomatic ICAS patients who failed medical management and were treated with balloon-mounted stents, 5.6% had strokes within 72 h, 3.9% were ischemic, and 1.7% were hemorrhagic. Recurrent strokes were reported in 3.7% at follow-up. While this patient population is different than ICAS-related ELVO patients, the safety profile of balloon-mounted stents in ICAS patients provides helpful data that could be used for future studies.
The use of intra-arterial thrombolitics such as alteplase (tPA) or urokinase has been suggested. However, given prior evidence of increased risk for hemorrhage, prior failure of intra-arterial tPA trials' use of intra-arterial thrombolitics is generally avoided (1, 47). One study evaluated clot composition in 37 patients with large vessel occlusion undergoing MT. In this study, patients with large artery atherosclerosis were found to have higher proportion of platelets and fibrin and lower proportion of red blood cells as compared with those with cardio-embolic occlusion (23). Given the platelet/fibrin-rich component of ICAS-related clots, the use of antiplatelet as first-line rescue therapy has been evaluated. Tirofiban is a short-acting glycoprotein IIb/IIIa inhibitor and competitively inhibits platelet aggregation mediated by fibrinogen. The use of low-dose tirofiban was evaluated on patients undergoing MT with second-generation SR evaluated in a prospective observational study in China. In this study, the use of low-dose tirofiban was not associated with increased risk of hemorrhage or long-term mortality (48). A recent study carried out in Korea compared the outcomes of using intra-arterial glycoprotein IIb/IIIa inhibitor infusion with those emergent angioplasty and found that both techniques resulted in a successful revascularization rate of about 95% with similar rates of symptomatic hemorrhage, 3-month functional independence, and mortality (49). However, one major disadvantage of intra-arterial tirofiban is late re-occlusion as reported in prior studies (31). Finally, the mechanism of stroke and location of lesion should take into account the approach to treatment, and response to intra-arterial antiplatelets, angioplasty, and/or stenting should be taken into account when attempting to identify the ideal treatment approach for ICAS-related ELVO (50).

**FUTURE DIRECTIONS**

ICAS-related ELVO remains a challenging and poorly understood entity. Current evidence shows good safety and efficacy outcomes of rescue treatments with balloon angioplasty and/or stenting; however, evidence is limited to retrospective studies. Future direction should focus on attempting to identify this group of patients pre-procedurally utilizing calcium burden, collateral status, location of occlusion, and stroke severity on
arrival. In addition, while there is good evidence to support the use of balloon angioplasty and/or stenting, the ideal balloon and stent used are unknown and often dependent on the interventionist preference.

Furthermore, the amount of balloon angioplasty to be performed should also be better studied. Similar to refractory ICAS in the subacute setting, submaximal angioplasty could offer similar results to maximal angioplasty with lower complication rates. Finally, the long-term impact of angioplasty and/or stenting as well as intra-arterial treatment should be studied. Future studies should focus on assessing vessel patency on follow-up imaging.

REFERENCES

1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2019) 50:e344–418. doi: 10.1161/STR.0000000000002021

2. Dekker I, Geraedts VJ, Hund H, Cannegieter SC, Nooghe RA, Goyal M, et al. Importance of reperfusion status after intra-arterial thrombectomy for prediction of outcome in anterior circulation large vessel stroke. Interv Neurol. (2018) 7:137–47. doi: 10.1159/000486246

3. Kasab SA, Almallouhi E, Alawieh A, Wolfe S, Fargen KM, Arthur AS, et al. Outcomes of rescue endovascular treatment of emergent large vessel occlusion in patients with underlying intracranial atherosclerosis: insights from STAR. J Am Heart Assoc. (2021) 10:e020195. doi: 10.1161/JAHA.120.020195

4. Tsang ACO, Ooru E, Klosteranjc JM, Yang LH, Lau KK, Tsang FCP, et al. Thrombectomy outcomes of intracranial atherosclerosis-related occlusions. Stroke. (2019) 50:1460–6. doi: 10.1161/STROKEAHA.119.024889

5. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpальzer M, Wakhloo A. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA Neurol. (2015) 313:1240–8. doi: 10.1001/jama.2015.1693

6. Yu SC, Cheng HK, Cheng PW, Liu WM, Leung KM, Tan CB, et al. Angioplasty and stenting for intracranial atherosclerotic stenosis: position statement of the Hong Kong Society of Interventional and Therapeutic Neuroradiology. Hong Kong Med J. (2013) 19:69–73.

7. Wang Y, Zhao X, Liu L, Soo YO, Yu P, Pan Y, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke. (2014) 45:663–9. doi: 10.1161/STROKEAHA.113.003508

8. White H, Boden-Alba B, Wang C, Elkind MS, Rundek T, Wright CB, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation. (2005) 111:1327–31. doi: 10.1161/01.CIR.0000157736.19539.D0

9. Baek JH, Kim BM, Heo JH, Kim DJ, Nam HS, Kim YD. Outcomes of endovascular treatment for acute intracranial atherosclerosis-related large vessel occlusion. Stroke. (2018) 49:2699–705. doi: 10.1161/STROKEAHA.118.022327

10. Al Kasab S, Almadidy Z, Spiotta AM, Turk AS, Chaudry MJ, Hungerford JP, et al. Endovascular treatment for AIS with underlying ICAD. J Neurointerv Surg. (2017) 9:498–51. doi: 10.1136/neurintsurg-2016-012529

11. Dobrocky T, Kaesmacher J, Bellwald S, Pichowiak E, Mosimann PJ, Zibold E, et al. Stent-retriever thrombectomy and rescue treatment of m1 occlusions due to underlying intracranial atherosclerotic stenosis: cohort analysis and review of the literature. Cardiovasc Inter Interv. (2019) 42:863–72. doi: 10.1007/s00270-019-02187-9

12. Gasco G, Lobotesis K, Machi P, Maldonado I, Vendrell J, Riquelme C, et al. Stent retrievers in acute ischemic stroke: complications and failures during the perioperative period. Am J Neuroradiol. (2014) 35:734–40. doi: 10.3174/ajnr.A3746

13. Lee JS, Hong JM, Kim JS. Diagnostic and therapeutic strategies for acute intracranial atherosclerosis-related occlusions. J Stroke. (2017) 19:143–51. doi: 10.5853/jos.2017.00626

14. Al Kasab S, Derdeyn CP, Guerrero WR, Limaye K, Shaban A, Adams HP. Intra-arterial large and medium artery atherosclerotic disease and stroke. J Stroke Cerebrovasc Dis. (2018) 27:1723–32. doi: 10.1016/j.jstrokecerebrovasdis.2018.02.050

15. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. (2013) 12:1106–14. doi: 10.1016/S1474-4422(13)70195-9

16. Leng X, Lan L, Ip HL, Abrego J, Scalzo F, Liu H, et al. Hemodynamics and stroke risk in intracranial atherosclerotic disease. Ann Neurol. (2019) 85:752–64. doi: 10.1002/ana.25456

17. Kim SJ, Morales JM, Yaghi S, Honda T, Scalzo F, Hinman JD, et al. Intracranial atherosclerotic disease mechanistic subtypes drive hypoperfusion patterns. J Neuroimaging. (2021) 31:686–90. doi: 10.1111/jon.12863

18. Yaghi S, Prabhatkar S, Khatri P, Liebeskind DS. Intracranial atherosclerotic disease. Stroke. (2019) 50:1286–93. doi: 10.1161/STROKEAHA.118.024147

19. Liebeskind DS. Precision medicine for intracranial atherosclerotic disease. Front Neurol. (2021) 12:646734. doi: 10.3389/fneur.2021.646734

20. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res. (2017) 120:502–13. doi: 10.1161/CIRCRESAHA.116.308441

21. Wabnitz AM, Derdeyn CP, Fiorella DJ, Lynn MJ, Cotsonis GA, Liebeskind DS, et al. Hemodynamic markers in the anterior circulation as predictors of recurrent stroke in patients with intracranial stenosis. Stroke. (2018) 49:2008040. doi: 10.1161/STROKEAHA.118.020840

22. Kang D-H, Yoon W. Current opinion on endovascular therapy for emergent large vessel occlusion due to underlying intracranial atherosclerotic stenosis. J Stroke Cerebrovasc Dis. (2019) 20:739–48. doi: 10.3389/jscr.2018.00809

23. Kim SK, Yoon W, Kim TS, Kim HS, Hoo JW, Park MS. Histologic analysis of retrieved clots in acute ischemic stroke: correlation with stroke etiology and gradient-echo MRI. AJNR Am J Neuroradiol. (2015) 36:1756–62. doi: 10.3174/ajnr.A4402

24. Suh HL, Hong JM, Lee KS, Han M, Choi JW, Kim JS, et al. Imaging predictors for atherosclerosis-related intracranial large artery occlusions in acute anterior circulation stroke. J Stroke. (2016) 18:352–4. doi: 10.5853/jos.2016.00283

25. Tsang ACO, Lau KK, Tsang FCP, Tse MMY, Lee R, Lui WM. Severity of intracranial carotid artery calcification in intracranial atherosclerosis-related occlusion treated with endovascular thrombectomy. Clin Neurol Neurosurg. (2018) 174:214–6. doi: 10.1016/j.clineuro.2018.09.030

26. Kim YW, Hong JM, Park DG, Choi JW, Kang DH, Kim YS, et al. Effect of intracranial atherosclerotic disease on endovascular treatment for patients with acute vertebralbasilar occlusion. AJNR Am J Neuroradiol. (2016) 37:2072–8. doi: 10.3174/ajnr.A4844

27. Ben Hassen W, Malley G, Boulouis G, Clarençon F, Bartolini B, Bourriche R, et al. Inter- and intraobserver reliability for angiographic leptomeningeal collateral flow assessment by the American Society

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) scale. J Neurointerv Surg. (2019) 11:338–41. doi: 10.1136/neurintsurg-2018-014185

28. Baek JH, Kim BM, Kim JW, Kim DJ, Heo JH, Nam HS, et al. Utility of leptomeningeal collaterals in predicting intracranial atherosclerosis-related large vessel occlusion in endovascular treatment. J Clin Med. (2020) 9:2784. doi: 10.3390/jcm9092784

29. Tan Y, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol. (2009) 30:525–31. doi: 10.3174/ajnr.A1408

30. Yin NS, Benavides S, Starkman S, Liebeskind DS, Saver JA, Salamon N, et al. Utility of leptomeningeal collaterals in predicting intracranial atherosclerosis-related large vessel occlusion in endovascular treatment. J Clin Med. (2020) 9:2784. doi: 10.3390/jcm9092784

31. Kang DH, Kim YW, Hwang YH, Park SP, Kim YS, Baik SK, et al. Instant reocclusion in stroke: a clinicopathologic study of 5 patients. Stroke. (2010) 41:938–47. doi: 10.1161/STROKEAHA.109.576793

32. Yoon W, Kim SK, Park MS, Kim BC, Kang HK. Endovascular treatment and the outcomes of atherosclerotic intracranial stenosis in patients with hyperacutie stroke. Neurosurgery. (2015) 76:680–6. doi: 10.1227/NEU.0000000000000694

33. Mathias-Guiu JA, Serna-Candel C, Mathias-Guiu J. Stroke etiology determines effectiveness of retrievable stents. J Neurointerv Surg. (2014) 6:e11. doi: 10.1136/neurintsurg-2012-010395

34. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella DJ, Turan TN, Fiorella D, et al. Steenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. (2005) 352:1305–16. doi: 10.1056/NEJMoa040303

35. Yoon W, Kim SK, Park MS, Kim BC, Kang HK. Endovascular treatment and the outcomes of atherosclerotic intracranial stenosis in patients with hyperacute stroke. Neurosurgery. (2015) 76:680–6. doi: 10.1227/NEU.0000000000000694

36. Lapergue B, Blanc R, Gory B, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: The aster randomized clinical trial. JAMA. (2017) 318:443–52. doi: 10.1001/jama.2017.9644

37. Teng D, Pannell JS, Rennert RC, Li J, Li YS, Wong VW, et al. Endothelial trauma from mechanical thrombectomy in acute stroke: in vitro live-cell platform with animal validation. Stroke. (2015) 46:1099–106. doi: 10.1161/STROKEAHA.114.007494

38. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. (2014) 11:639. doi: 10.1038/nrcardio.2014.118

39. Turk III AS, Siddiqui A, Fifi JT, De Leacy RA, Fiorella DJ, Gu E, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. The Lancet. (2019) 393:998–1008. doi: 10.1016/S0140-6736(19)30297-1

40. du Z, Meng J, Yu S, Tian C, Cao X, Liu X, et al. Weighing in on the off-label use: initial experience of neuroform EZ stenting for intracranial arterial stenosis in 45 patients. Front Neurol. (2018) 9:852. doi: 10.3389/fneur.2018.00852

41. Seyedsaadat SM, Yolcu YU, Neuhaus A, Rizvi A, Alzuabi M, Murad MH, et al. Submaximal angioplasty in the treatment of patients with symptomatic ICAD: a systematic review and meta-analysis. J NeuroInterv Surg. (2020) 12:380–5. doi: 10.1136/neurintsurg-2019-015451

42. Abraham P, Scott Pannell J, Santiago-Dieppa DR, Cheung V, Steinberg J, Wali A, et al. Vessel wall signal enhancement on 3-T MRI in acute stroke patients after stent retriever thrombectomy. Neurosurg Focus. (2017) 42:E20. doi: 10.3171/2017.1.FOCUS16492

43. Jankowitz BT, Hanel R, Jadhav AP, Loy DN, Frei D, Siddiqui AH, et al. Neuroform atlas stent system for the treatment of intracranial aneurysm: primary results of the atlas humanitariand device exemption cohort. J Neurointerv Surg. (2019) 11:801–6. doi: 10.1136/neurintsurg-2018-014455

44.Mohammed MN, Nogueira RG, Tekle W, Ortega-Gutierrez S, Faroqui M, Zevallos CR, et al. Safety and efficacy of balloon-mounted stent in the treatment of symptomatic intracranial atherosclerotic disease: a multicenter experience. J Neurointerv Surg. (2021) neurint surg:2021-017818. doi: 10.1136/neurintsurg-2021-017818

45. Furlan A, Higashida R, Wechsler L, Gent M, Rowlie H, Kase C, et al. Intracranial prourokinase for acute ischemic stroke The PROACT II study: a randomized controlled trial Prolyse in Acute Cerebral Thromboembolism. JAMA. (1999) 282:2003–11. doi: 10.1001/jama.282.21.2003

46. Zhao W, Che R, Shang S, Wu C, Li C, Wu L, et al. Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy. Stroke. (2017) 48:3289–94. doi: 10.1161/STROKEAHA.117.019193

47. Jankowitz DH, Yoon W, Kim SK, Baek BH, Lee YY, Kim YW, et al. Endovascular treatment for emergent large vessel occlusion due to severe intracranial atherosclerotic stenosis. J Neurosurg. (2018) 130:1–8. doi: 10.3171/2018.1.JNS172350

48. Samaniego EA, Shaban A, Ortega-Gutierrez S, Roa JA, Hasan DM, Derdeyn C, et al. Stroke mechanisms and outcomes of isolated symptomatic basilar artery stenosis. Stroke Vasc Neurol. (2019) 4:189–97. doi: 10.1136/svn-2019-000246

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Al Kasab, Almallouhi and Spiotta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.